Monitor upcoming clinical data presentations for ARV-393 at ASH in December 2026 and ARV-027/ARV-6723 data in 2027, as these are the primary value drivers for this pre-commercial biotech. Cash runway into H2 2028 provides a long operational runway but no near-term revenue catalyst.
Drugs in focus
ARVN drug pipeline →ARV-393
● Neutral Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- At least several years away. The drug is in Phase 1 dose escalation (estimated primary completion March 2028), requiring Phase 2/3 trials and regulatory review before any potential approval.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $7.09entry
- T+1 · 13d ago +4.65%α +3.00% · $7.42
- T+5 · 7d ago −2.40%α −1.81% · $6.92
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arvinas reported Q3 2026 revenue of $0.5M, down from $41.9M a year ago, as Pfizer collaboration revenue did not recur following the Rigel license. GAAP net loss was $53.9M ($0.82 per share) vs. consensus EPS of -$0.95, a beat on the bottom line. The company highlighted upcoming clinical data readouts for ARV-393, ARV-027, and ARV-6723 in late 2026 and 2027, and reiterated its cash runway into H2 2028.
Key Financial Metrics
Key Facts
- Q3 2026 revenue was $0.5M vs. $41.9M in Q3 2025; the decrease was driven by non-recurrence of Pfizer collaboration revenue and milestone payments.
- GAAP net loss was $53.9M ($0.82 per share) vs. consensus EPS estimate of -$0.95, a beat.
- Cash, cash equivalents, restricted cash, and marketable securities were $558.9M as of September 30, 2026, down from $685.4M at year-end 2025.
- R&D expenses decreased to $46.9M from $64.7M year-over-year, primarily due to lower external and personnel costs.
- Company expects cash runway into the second half of 2028.
- Initiated dosing in Phase 1/2 trial of ARV-6723 (HPK1 degrader) and Phase 1 trial of ARV-027 (polyQ-AR degrader) in healthy volunteers.
- Upcoming milestones include ARV-393 monotherapy data at ASH (Q4 2026), ARV-027 initial data (1H 2027), and ARV-6723 initial monotherapy data (2H 2027).
Financial Impact
Revenue declined $41.4M YoY; net loss of $53.9M vs. $35.1M loss in Q3 2025; cash burn of $126.5M in nine months.
Risk Factors
- Revenue collapsed to near-zero after Pfizer collaboration revenue ended; reliance on Rigel royalties is minimal ($0.5M).
- All pipeline candidates are in early-stage clinical trials with no approved products; clinical failure risk is high.
- IND for ARV-102 remains on hold in the U.S., limiting the addressable patient population for the PSP trial.
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394044 |
Track record
21 reports on ARVN
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Viewing Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers